Hence, future clinical trials are suggested on patients with hypoparathyroidism before treatment to investigate the FGF23 functions and its interaction with PTH more accurately, considering tissue iron evaluation e.g. in liver. This evidence concerns the gene PTH and hypoparathyroidism.